We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 245

Federal Circuit notes high burden of invoking inherency for obviousness

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • December 5 2014

In Par Pharmaceutical Inc. v. Twi Pharmaceuticals, Inc., the Federal Circuit vacated and remanded the district court decision holding the Par claims

Federal Circuit says secret prior art is prior art for all purposes

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • December 11 2014

In Tyco Healthcare Group LP v. Ethicon Endo-Surgery, Inc., the Federal Circuit agreed with the district court that Ethicon's prototype constituted

First post grant review petition shows that amending claims is not child's play

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • August 11 2014

The first Post Grant Review petition visible to the public was filed August 5, 2014, against U.S. Patent 8,684,420. The patent was granted from an

Federal Circuit finds distribution of glucose meters exhausts method patent claims

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • November 14 2013

In LifeScan Scotland, Ltd. V. Shasta Technologies, LLC, the Federal Circuit found that LifeScan's distribution of its One-Touch Ultra glucose meters

Federal Circuit finds hole in “this” priority claim

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • January 29 2014

In Medtronic CoreValve, LLC v. Edwards Lifesciences Corp., the Federal Circuit affirmed the district court's finding that the patent at issue was

District court doubts patent eligbility of Myriad BRCA claims

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • March 18 2014

In a decision issued March 10, 2014, Judge Shelby of the U.S. District Court for the District of Utah denied Myriad's motion for a preliminary

Federal Circuit looks for inventive concept in Sequenom patent

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • November 10 2014

On November 7, 2014, the Federal Circuit heard oral arguments in Aria Diagnostics, Inc. v. Sequenom, Inc., where Sequenom is appealing the district

Do pharmaceutical compositions have patent subject matter eligibility under the new USPTO guidelines?

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • March 10 2014

The USPTO's new patent subject matter eligibility guidelines (the "Guidelines") include examples that apply the multi-factored analysis mandated by

Federal Circuit hears arguments in other Myriad gene patents case

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • October 7 2014

On October 6, 2014, the Federal Circuit heard oral arguments in a case involving the claims of the Myriad gene patents that were not invalidated by

Federal Circuit overturns obviousness rejection based on non-analogous art

  • Foley & Lardner LLP
  • -
  • USA
  • -
  • September 29 2011

In In re Klein, the Federal Circuit reversed an obviousness rejection because the cited references were found to be non-analogous art